 | • レポートコード：MRC2301F0103 • 出版社/出版日：Transparency Market Research / 2022年11月3日 • レポート形態：英文、PDF、211ページ • 納品方法：Eメール • 産業分類：医療 |
| Single User | ￥869,250 (USD5,795) | ▷ お問い合わせ |
| Multi User | ￥1,319,250 (USD8,795) | ▷ お問い合わせ |
| Corporate License | ￥1,769,250 (USD11,795) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| トランスペアレンシー・マーケット・リサーチ社の当調査資料では、世界の膣炎診断市場について総合的に調査・分析を行い、序論、仮定・調査手法、市場概要、主要インサイト、検査タイプ別（核酸増幅アッセイ、DNAプローブ、臨床検査）分析、疾患別（細菌性膣炎、外陰カンジダ症、トリコモナス膣炎、その他）分析、エンドユーザー別（病院、専門クリニック、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ）分析、競争状況、企業情報などの項目を掲載しています。なお、当市場の主要企業には、Abbott Laboratories、Atrida、Becton, Dickinson and Company、Cepheid (Danaher Corporation)、F. Hoffmann-La Roche Ltd.、Hologic, Inc.、Laboratory Corporation of America Holdings、QIAGEN、Quest Diagnostics Incorporated、Quidel Corporationなどが含まれています。 ・序論 ・仮定・調査手法 ・市場概要 ・主要インサイト ・世界の膣炎診断市場規模：検査タイプ別 - 核酸増幅アッセイの市場規模 - DNAプローブの市場規模 - 臨床検査の市場規模 ・世界の膣炎診断市場規模：疾患別 - 細菌性膣炎の市場規模 - 外陰カンジダ症の市場規模 - トリコモナス膣炎の市場規模 - その他疾患の市場規模 ・世界の膣炎診断市場規模：エンドユーザー別 - 病院における市場規模 - 専門クリニックにおける市場規模 - その他エンドユーザーにおける市場規模 ・世界の膣炎診断市場規模：地域別 - 北米の膣炎診断市場規模 - ヨーロッパの膣炎診断市場規模 - アジア太平洋の膣炎診断市場規模 - 中南米の膣炎診断市場規模 - 中東/アフリカの膣炎診断市場規模 ・競争状況 ・企業情報 |
Vaginitis Diagnostics Market – Scope of Report
TMR’s report on the global vaginitis diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global vaginitis diagnostics market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global vaginitis diagnostics market from 2022 to 2031.
The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the vaginitis diagnostics market.
Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global vaginitis diagnostics market.
The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global vaginitis diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global vaginitis diagnostics market.
The report delves into the competitive landscape of the global vaginitis diagnostics market. Key players operating in the global vaginitis diagnostics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global vaginitis diagnostics market profiled in this report.
RESEARCH METHODOLOGY
The research methodology will be a combination of exhaustive primary and secondary research to analyze the market vaginitis diagnostics.
Secondary Research
Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.
Secondary research sources that we typically refer, but are not limited to:
Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market
Specific Secondary Sources:
Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound
Primary Research
During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.
We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:
Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies
Participants who typically take part in such a process include, but are not limited to:
Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals
List of primary participants, but not limited to:
Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.
Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.
Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:
Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities
Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.
レポート目次1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Vaginitis Diagnostics Market
4. Market Overview
4.1. Introduction
4.1.1. Testing Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Vaginitis Diagnostics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Industry Events (New Product Launches/Key Mergers & Acquisitions)
5.2. Technological Advancements
5.3. Disease Incidence and Prevalence
5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short-/ Mid-/ Long-Term Impact)
6. Global Vaginitis Diagnostics Market Analysis and Forecast, by Testing Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Testing Type, 2017–2031
6.3.1. Nucleic Acid Amplification Assays
6.3.2. DNA Probe
6.3.3. Clinical Test
6.4. Market Attractiveness Analysis, by Testing Type
7. Global Vaginitis Diagnostics Market Analysis and Forecast, by Disease Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Disease Type, 2017–2031
7.3.1. Bacterial Vaginosis/Vaginitis
7.3.2. Vulvovaginal Candidiasis
7.3.3. Trichomoniasis
7.3.4. Others
7.4. Market Attractiveness Analysis, by Disease Type
8. Global Vaginitis Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Vaginitis Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Vaginitis Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Testing Type, 2017–2031
10.2.1. Nucleic Acid Amplification Assays
10.2.2. DNA Probe
10.2.3. Clinical Test
10.3. Market Value Forecast, by Disease Type, 2017–2031
10.3.1. Bacterial Vaginosis/Vaginitis
10.3.2. Vulvovaginal Candidiasis
10.3.3. Trichomoniasis
10.3.4. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Testing Type
10.6.2. By Disease Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Vaginitis Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Testing Type, 2017–2031
11.2.1. Nucleic Acid Amplification Assays
11.2.2. DNA Probe
11.2.3. Clinical Test
11.3. Market Value Forecast, by Disease Type, 2017–2031
11.3.1. Bacterial Vaginosis/Vaginitis
11.3.2. Vulvovaginal Candidiasis
11.3.3. Trichomoniasis
11.3.4. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Testing Type
11.6.2. By Disease Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Vaginitis Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Testing Type, 2017–2031
12.2.1. Nucleic Acid Amplification Assays
12.2.2. DNA Probe
12.2.3. Clinical Test
12.3. Market Value Forecast, by Disease Type, 2017–2031
12.3.1. Bacterial Vaginosis/Vaginitis
12.3.2. Vulvovaginal Candidiasis
12.3.3. Trichomoniasis
12.3.4. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Testing Type
12.6.2. By Disease Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Vaginitis Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Testing Type, 2017–2031
13.2.1. Nucleic Acid Amplification Assays
13.2.2. DNA Probe
13.2.3. Clinical Test
13.3. Market Value Forecast, by Disease Type, 2017–2031
13.3.1. Bacterial Vaginosis/Vaginitis
13.3.2. Vulvovaginal Candidiasis
13.3.3. Trichomoniasis
13.3.4. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Testing Type
13.6.2. By Disease Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Vaginitis Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Testing Type, 2017–2031
14.2.1. Nucleic Acid Amplification Assays
14.2.2. DNA Probe
14.2.3. Clinical Test
14.3. Market Value Forecast, by Disease Type, 2017–2031
14.3.1. Bacterial Vaginosis/Vaginitis
14.3.2. Vulvovaginal Candidiasis
14.3.3. Trichomoniasis
14.3.4. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Testing Type
14.6.2. By Disease Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Market Share Analysis, by Company, 2021
15.3. Company Profiles
15.3.1. Laboratory Corporation of America Holdings
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Product Portfolio
15.3.1.3. Company Financial
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Cepheid (Danaher Corporation)
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Product Portfolio
15.3.2.3. Company Financial
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. Abbott Laboratories
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Product Portfolio
15.3.3.3. Company Financial
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. QIAGEN
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Product Portfolio
15.3.4.3. Company Financial
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. F. Hoffmann-La Roche Ltd.
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Product Portfolio
15.3.5.3. Company Financial
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Hologic, Inc.
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Product Portfolio
15.3.6.3. Company Financial
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Quidel Corporation
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Product Portfolio
15.3.7.3. Company Financial
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. Quest Diagnostics Incorporated
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Product Portfolio
15.3.8.3. Company Financial
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Atrida
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Product Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Strategic Overview
15.3.10. Becton, Dickinson and Company
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Product Portfolio
15.3.10.3. Company Financial
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview